KASMEJ
Kastamonu Medical Journal

Kastamonu Medical Journal regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

eISSN: 2757-9336
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Is the P2/Ms score a reliable method for detecting fibrosis stage in patients with steatohepatitis?
Abstract
Aims: This study aimed to evaluate the utility of the P2/MS score in detecting liver fibrosis severity in patients with non-alcoholic steatohepatitis (NASH), alongside established noninvasive markers such as FIB-4 and APRI. Additionally, we sought to examine changes in these markers across patients with non-alcoholic fatty liver disease (NAFLD), NASH, and healthy controls, and their relationship with the NAFLD activity score (NAS).
Methods: A total of 264 patients were retrospectively analyzed: 99 healthy controls, 100 NAFLD patients, and 65 NASH patients diagnosed by liver biopsy. Laboratory parameters and noninvasive fibrosis scores (FIB-4, APRI, P2/MS) were compared among groups. In the NASH subgroup, we evaluated the ability of these indices to distinguish fibrosis stages and NAS?5. Statistical analysis was performed using IBM SPSS v25.0.
Results: The FIB-4 Index effectively distinguished fibrosis stages, particularly METAVIR 3&4 versus lower stages (p<0.001), and APRI also showed significant discriminatory capacity (p=0.005). In contrast, the P2/MS score did not show any significant association with fibrosis stages (p=0.137) or with group classification (control, NAFLD, NASH). Similarly, while FIB-4 and APRI increased progressively from control to NAFLD to NASH (p<0.001), P2/MS values remained statistically unchanged across groups. None of the noninvasive scores-including P2/MS-were effective in predicting NAS?5.
Conclusion: The P2/MS score failed to demonstrate clinical utility in differentiating fibrosis severity or distinguishing between NAFLD, NASH, and healthy individuals. In contrast, FIB-4 and APRI were significantly more reliable in identifying advanced fibrosis in NASH patients. These findings do not support the use of the P2/MS score in routine clinical assessment of NASH-related fibrosis.

Keywords : NAFLD, NASH, P2/MS, APRI, FIB4, liver fibrosis, NAS score

Download Article


1. Kabarra K, Golabi P, Younossi ZM. Nonalcoholic steatohepatitis: global impact and clinical consequences. Endocr Connect. 2021;10(10): R240-R247. doi:10.1530/EC-21-0048
2. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20. doi:10.1038/nrgastro.2017.109
3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1):73-84. doi:10.1002/hep.28431
4. Ekstedt M, Hagstr&ouml;m H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547-1554. doi:10.1002/hep.27368
5. Dufour JF, Anstee QM, Bugianesi E, et al. Current therapies and new developments in NASH. Gut. 2022. doi:10.1136/gutjnl-2021-326874
6. Juluri R, Vuppalanchi R, Olson J, et al. Generalizability of the nonalcoholic steatohepatitis clinical research network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol. 2011;45(1):55-58. doi:10.1097/MCG.0b013e3181dd1348
7. Kim BK, Han KH, Park JY, et al. External validation of P2/MS and comparison with other simple non-invasive indices for predicting liver fibrosis in HBV-infected patients. Dig Dis Sci. 2010;55(9):2636-2643. doi: 10.1007/s10620-009-1070-3
8. Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015;19(5):597-601. doi:10.4103/2230-8210.163172
9. Mansour-Ghanaei R, Mansour-Ghanaei F, Naghipour M, Joukar F. Biochemical markers and lipid profile in nonalcoholic fatty liver disease patients in the PERSIAN Guilan cohort study (PGCS), Iran.J Family Med Prim Care. 2019;8(3):923-928. doi:10.4103/jfmpc.jfmpc_243_18
10. Chao YL, Wu PY, Huang JC, et al. Hepatic steatosis is associated with high white blood cell and platelet counts. Biomedicines. 2022;10(4):892. doi:10.3390/biomedicines10040892
11. Siddiqui MS, Yamada G, Vuppalanchi R, et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol. 2019;17(9):1877-1885.e5. doi:10.1016/j.cgh.2018. 12.031
12. Chalasani N, Abdelmalek MF, Loomba R, et al. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Liver Int. 2019;39(5):924-932. doi:10.1111/liv.13974
13. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66(5):1486-1501. doi:10.1002/hep.29302
14. Yu SJ, Kim DH, Lee JH, et al. Validation of P2/MS and other noninvasive fibrosis scoring systems in the Korean population with nonalcoholic fatty liver disease. Korean J Gastroenterol. 2011;57(1):19-27. doi:10.4166/kjg.2011.57.1.19
15. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-1048. doi:10.1016/j.metabol.2015.12.012 </ol> <p>
Article available in :
Volume 5, Issue 4, 2025
Page : 259-264
https://doi.org/10.51271/KMJ-0222
Article Information
Received : 28 Ara 2024
Accepted : 21 Tem 2025
Published : 02 Ara 2025
Corresponding Author :

İdris Kurt: Department of Gastroenterology, Faculty of Medicine, Trakya University Edirne, Turkiye

[email protected]
Citation : Karahanlı C, Topal F, Kurt İ, Taşdemir Ü, Gündüz İ. Is the P2/Ms score a reliable method for detecting fibrosis stage in patients with steatohepatitis? Kastamonu Med J. 2025;5(4):259-264.

Read: 25
Download : 37
Cited: 0
_Footer